Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Learn the long-term average annual return for index funds and how it informs portfolio construction, diversification, and risk management.
27,739 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Chewy’s stock action in May left investors asking what happened and what comes next. This article breaks down the cat...
As February nears its end in 2026, three Schwab ETFs stand out for investors positioning before March. They offer low...
Income-focused investors face a tricky mood: chase reliable payouts or risk capital. Learn about three high-yield div...
A record M&A surge, pegged at roughly $4 trillion for 2026, is shaping the market. Wall Street is weighing whether a ...
The Strait of Hormuz remains blocked by a widening U.S.-Iran conflict, fueling volatility in oil prices and household...
Plenty of retirees rush to claim Social Security, but a single number can change everything: your break-even age. Lea...
The Starship launch is drawing global attention, but SpaceX remains private. This guide explains what that means for ...
Costco's stock keeps breaking the $1,000 threshold, fueling split rumors. This guide unpacks why the price stays high...
Explore how Jean Eric Salata leads EQT Group to build durable value across private equity and beyond. This article di...
AMD just struck a landmark deal with a global AI cloud leader. This article breaks down what the contract means for r...
This comprehensive guide breaks down Exzeo’s Q1 2026 results, reveals the drivers behind exzeo (xzo) 2026 earnings, a...